TY - JOUR T1 - Clinical and molecular features of V600E and non-V600E BRAF mutations in NSCLC – a retrospective monocentric observational study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2020.1689 VL - 56 IS - suppl 64 SP - 1689 AU - Carolin Lips AU - Gesa Rafflenbeul AU - Torsten Gerriet Blum AU - Jens Kollmeier AU - Daniel Misch AU - Monica Schäfer AU - Susann Stephan-Falkenau AU - Anna Streubel AU - Sebastian Thiel AU - Thomas Mairinger AU - Torsten Bauer Y1 - 2020/09/07 UR - http://erj.ersjournals.com/content/56/suppl_64/1689.abstract N2 - Background: BRAF mutations, both V600E and non V600E, are found in 2-6% of NSCLC. The efficacy of the BRAF inhibitor dabrafenib with the MEK inhibitor trametinib in metastatic BRAF V600E+ NSCLC has led to a rapid FDA and EMA approval. Evidence on distinct characteristics in V600E and non V600E-mutated BRAF NSCLC pts. is so far limited.Methods: In a retrospective analysis, we assessed all BRAF mutated NSCLC pts. (7/09-12/19) and compared clinical, molecular and prognostic factors between V600E and non-V600E mutations. BRAF mutations were detected by PCR (2009-17) and NGS (since 2018).Results: Out of the 71 BRAF+ pts., V600E and non-V600E were detected in 30 pts. (42%) and 41 pts. (58%). Age, sex, smoking status and stage distribution were similar in both groups. Rates for most metastatic sites were comparable. No malignant pericardial effusions were seen in the non-V600E cohort. V600E+ mutations showed a higher frequency of PD-L1 positivity (p=0.018). Dabra/tram. was given in 8/15 stage IV V600E+ pts. as 1st line therapy (not available in other 7 pts. at diagnosis). 2 pts. received this combo after relapse. The median overall survival in V600E stage IV pts. treated with dabra./tram. and all stage IV BRAF pts. receiving standard chemotx differed with 479 days (95% CI 6-951 days) and 53 days (95% CI 0-237 days), respectively.Conclusions: V600E and non-V600E share many clinical features. However, a significantly higher rate of PD-L1 positive pts. was seen in the V600E cohort. The positive impact of dabra./tram. compared to standard chemotx in the clinical trial with V600E NSCLC patients was noticeable also in this retrospective analysis of real life pts.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1689.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -